E3 ligase mediated control of Foxp3 expression and immune suppression-mechanisms and potential as immunotherapeutic target
E3连接酶介导的Foxp3表达和免疫抑制机制的控制以及作为免疫治疗靶点的潜力
基本信息
- 批准号:10331033
- 负责人:
- 金额:$ 37.91万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-02-01 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:AchievementAdvanced Malignant NeoplasmAffectAnti-Inflammatory AgentsAutoimmuneAutoimmune DiseasesAutoimmunityBiochemicalBiologyCancer PatientCancer VaccinesCell CompartmentationCell NucleusCell physiologyCellsCharacteristicsChemicalsCytoplasmDetectionDevelopmentDiseaseDisease modelDissectionDown-RegulationDrug ScreeningElementsEnzymesFOXP3 geneGenerationsGeneticHomeostasisHost DefenseHumanIL2RA geneImmuneImmune mediated destructionImmune responseImmune systemImmunomodulatorsImmunosuppressionImmunotherapeutic agentImmunotherapyInfectionInflammatoryInterruptionInterventionInvestigational TherapiesKnock-outLeadLeukocytesLigaseLipopolysaccharidesMalignant NeoplasmsMalignant neoplasm of ovaryMediatingModelingModificationMolecularMusMutateOutcomePathologyPathway interactionsPharmacologyPhenotypePhosphorylationPhosphotransferasesPhysiologicalPlayPolyubiquitinationPost-Translational Protein ProcessingPost-Translational RegulationProcessProteinsRegulationRegulatory PathwayRegulatory T-LymphocyteReporterResearchRiskRoleRoswell Park Cancer InstituteSignal PathwaySignal TransductionSiteSmall Interfering RNAStimulusStressT-LymphocyteT-Lymphocyte SubsetsTestingTherapeuticTissuesTransgenic MiceTumor EscapeTumor ImmunityUbiquitinWorkanti-canceranti-tumor immune responsebasecancer immunotherapycell bankcytokineefficacy testingexperimental studyfitnessglycogen synthase kinase 3 beta inhibitorimmune activationimmunoregulationin vitro Modelin vivoinflammatory milieuinhibitorknock-downmelanomaneoplasm immunotherapyneoplastic cellnoveloverexpressionpreventresponserestraintscreeningside effecttargeted agenttranscription factortumortumor eradicationtumor growthtumor microenvironmentubiquitin-protein ligasevaccine efficacy
项目摘要
Project Summary
Tumor cells exploit mechanisms of immune regulation to evade detection and eradication by host defenses.
Foxp3+CD4+CD25+ regulatory T cell (Treg)-mediated immune suppression is crucial for immune evasion by
tumor cells and an obstacle for successful tumor immunotherapy. Hence, the ability to disrupt Treg function is
of major therapeutic significance. Recent work by us and others revealed that the key Treg transcription factor,
Foxp3 is subject to polyubiquitination-dependent posttranslational regulation. Particularly, we found the E3
ubiquitin ligase Stub1, which is induced in response to a range of stress signals, facilitates the degradation of
Foxp3 providing a potential target for dynamic modulation of Treg suppression. In the current proposal, we are
seeking to: 1) Dissect molecular signaling pathways involved in Stub1 expression and its post-translational
modification; 2) Understand the consequences of physiological Stub1 induction and genetic deletion for Treg
cell homeostasis, differentiation and function; and 3) Test pharmacological activators of Foxp3 ubquitination as
novel immunotherapic strategies to undermine immune suppression in the cancer setting. These studies will
expand our understanding of the mechanisms behind posttranslational Foxp3 regulation. Specifically, we will
further explore pathways determining Stub1 activity and expression, including the previously unappreciated
phosphorylation of the ligase by the kinase GS3Kβ. To this end, we will utilize biochemical approaches and
well-characterized models of in vitro and in vivo Treg function to establish the consequences of ablating these
pathways. Furthermore, pharmacological modifiers of the Stub1/Ubiquitin-dependent pathway for Foxp3
degradation (identified in a drug screen and previous studies) will be tested for efficacy as breakers of immune
suppression - a major obstacle for anti-cancer immunotherapy. This vetting will be carried out in an aggressive
murine melanoma model (in vivo) as well as in ex vivo studies of human leukocytes obtained from healthy
donors and advanced cancer patients. In so doing we will determine the potential therapeutic application of
modulating Stub1 activity to boost anti-tumor immunity. Our experiments may reveal novel modes of regulating
Stub1 activity and Foxp3 protein downregulation. Detailed assessment of physiological Stub1 induction and its
impact on Foxp3 and Treg function is predicted to demonstrate a potent therapeutic application. Use of Stub1-
activators in combination with proven checkpoint targeting agents may yield even better anti-tumor efficacy.
项目概要
肿瘤细胞利用免疫调节机制来逃避宿主防御的检测和根除。
Foxp3+CD4+CD25+调节性T细胞(Treg)介导的免疫抑制对于免疫逃避至关重要
肿瘤细胞是肿瘤免疫治疗成功的障碍,因此,破坏 Treg 功能的能力是关键。
我们和其他人最近的工作揭示了关键的 Treg 转录因子,
Foxp3 受到多泛素化依赖性翻译后调控,特别是,我们发现了 E3。
泛素连接酶 Stub1 是响应一系列应激信号而诱导的,可促进泛素连接酶 Stub1 的降解
Foxp3 为 Treg 抑制的动态调节提供了潜在的靶标。
寻求:1) 剖析 Stub1 表达及其翻译后相关的分子信号通路
2) 了解生理性Stub1诱导和基因缺失对Treg的影响
细胞稳态、分化和功能;以及 3) Foxp3 泛素化的测试逻辑药物激活剂
这些研究将开发出新的免疫治疗策略来破坏癌症环境中的免疫抑制。
具体来说,我们将扩大我们对翻译后 Foxp3 调控机制的理解。
进一步探索决定 Stub1 活性和表达的途径,包括以前未被重视的途径
激酶 GS3Kβ 对连接酶进行磷酸化 为此,我们将利用生化方法和
体外和体内 Treg 功能的良好表征模型,以确定消除这些功能的后果
此外,Foxp3 的 Stub1/泛素依赖性途径的药理学修饰剂。
降解(在药物筛选和之前的研究中确定)将被测试作为免疫破坏者的功效
抑制——抗癌免疫治疗的一个主要障碍。这种审查将以积极的方式进行。
鼠黑色素瘤模型(体内)以及从健康人获得的人类白细胞的离体研究
在此过程中,我们将确定捐赠者和晚期癌症患者的潜在治疗应用。
调节 Stub1 活性以增强抗肿瘤免疫力我们的实验可能揭示新的调节模式。
Stub1 活性和 Foxp3 蛋白下调的生理学 Stub1 诱导及其的详细评估。
对 Foxp3 和 Treg 功能的影响预计将证明 Stub1- 的有效治疗应用。
激活剂与经过验证的检查点靶向剂相结合可能会产生更好的抗肿瘤功效。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nemo-like Kinase Drives Foxp3 Stability and Is Critical for Maintenance of Immune Tolerance by Regulatory T Cells.
Nemo 样激酶可驱动 Foxp3 稳定性,对于调节性 T 细胞维持免疫耐受至关重要。
- DOI:
- 发表时间:2019
- 期刊:
- 影响因子:8.8
- 作者:Fleskens, Veerle;Minutti, Carlos M;Wu, Xingmei;Wei, Ping;Pals, Cornelieke E G M;McCrae, James;Hemmers, Saskia;Groenewold, Vincent;Vos, Harm;Rudensky, Alexander;Pan, Fan;Li, Huabin;Zaiss, Dietmar M;Coffer, Paul J
- 通讯作者:Coffer, Paul J
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DREW M. PARDOLL其他文献
DREW M. PARDOLL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DREW M. PARDOLL', 18)}}的其他基金
Role of YAP in Treg Function and YAP Targeting for Cancer Immunotherapy
YAP 在 Treg 功能中的作用和 YAP 靶向癌症免疫治疗
- 批准号:
10547779 - 财政年份:2018
- 资助金额:
$ 37.91万 - 项目类别:
Role of YAP in Treg Function and YAP Targeting for Cancer Immunotherapy
YAP 在 Treg 功能中的作用和 YAP 靶向癌症免疫治疗
- 批准号:
10330418 - 财政年份:2018
- 资助金额:
$ 37.91万 - 项目类别:
Mechanisms of TH17 Inflammation-Induced Colon Carcihogenesis
TH17炎症诱导的结肠癌发生机制
- 批准号:
8455705 - 财政年份:2010
- 资助金额:
$ 37.91万 - 项目类别:
Enterotoxigenic Bacteroides fragilis: A bacterial promoter of colon oncogenesis
产肠毒素脆弱拟杆菌:结肠癌发生的细菌启动子
- 批准号:
8303450 - 财政年份:2010
- 资助金额:
$ 37.91万 - 项目类别:
Enterotoxigenic Bacteroides fragilis: A bacterial promoter of colon oncogenesis
产肠毒素脆弱拟杆菌:结肠癌发生的细菌启动子
- 批准号:
8707985 - 财政年份:2010
- 资助金额:
$ 37.91万 - 项目类别:
The Role of EOS in Regulatory T-cell Biology.
EOS 在调节性 T 细胞生物学中的作用。
- 批准号:
8289608 - 财政年份:2010
- 资助金额:
$ 37.91万 - 项目类别:
PD-1/PD-L1 modulation in cancer therapy
癌症治疗中的 PD-1/PD-L1 调节
- 批准号:
10355495 - 财政年份:2010
- 资助金额:
$ 37.91万 - 项目类别:
The Role of EOS in Regulatory T-cell Biology.
EOS 在调节性 T 细胞生物学中的作用。
- 批准号:
7947180 - 财政年份:2010
- 资助金额:
$ 37.91万 - 项目类别:
The Role of EOS in Regulatory T-cell Biology.
EOS 在调节性 T 细胞生物学中的作用。
- 批准号:
8683077 - 财政年份:2010
- 资助金额:
$ 37.91万 - 项目类别:
相似海外基金
Targeting Transglutaminase 2 in cancer cachexia
靶向转谷氨酰胺酶 2 治疗癌症恶病质
- 批准号:
10442384 - 财政年份:2020
- 资助金额:
$ 37.91万 - 项目类别:
Targeting Transglutaminase 2 in cancer cachexia
靶向转谷氨酰胺酶 2 治疗癌症恶病质
- 批准号:
10174890 - 财政年份:2020
- 资助金额:
$ 37.91万 - 项目类别:
Targeting Transglutaminase 2 in cancer cachexia
靶向转谷氨酰胺酶 2 治疗癌症恶病质
- 批准号:
10442384 - 财政年份:2020
- 资助金额:
$ 37.91万 - 项目类别:
Geographic and Racial Disparities in Mammography Screening and Barriers to Receiving Care
乳房 X 线摄影筛查的地理和种族差异以及接受护理的障碍
- 批准号:
10040239 - 财政年份:2020
- 资助金额:
$ 37.91万 - 项目类别:
Targeting Transglutaminase 2 in cancer cachexia
靶向转谷氨酰胺酶 2 治疗癌症恶病质
- 批准号:
10032715 - 财政年份:2020
- 资助金额:
$ 37.91万 - 项目类别: